Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs dexmedetomidine for postoperative gastrointestinal function after laparoscopic colon cancer surgery
ChiCTR2600116036Phase 4Not yet recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in colon cancer and Postoperative gastrointestinal dysfunction (POGD) comparing Dexmedetomidine group with Remimazolam group (2 arms). Primary endpoint: Time to first flatus after surgery. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
remimazolamdexmedetomidine
03
Conditions
colon cancerPostoperative gastrointestinal dysfunction (POGD)
Beyond the preview
Go deeper on ChiCTR2600116036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116036.